10-Q: Avid Bioservices Reports 6% Revenue Increase in First Fiscal Quarter, Backlog Reaches $219 Million

Avid Bioservices saw a 6% increase in revenue to $40.2 million in the first fiscal quarter, driven by growth in process development, and ended the quarter with a backlog of $219 million.

Summary

• Avid Bioservices reported a revenue of $40.2 million for the three months ended July 31, 2024, a 6% increase compared to $37.7 million for the same period last year.
• The increase in revenue was primarily due to a rise in process development revenues, which reached $6.2 million, up from $4.3 million in the prior year.
• Manufacturing revenues also saw a slight increase, reaching $34.0 million compared to $33.4 million in the same period last year.
• The company's gross profit was $5.7 million, with a gross margin of 14%, compared to $4.1 million and 11% gross margin in the prior year.
• Operating expenses increased to $8.2 million, up from $6.3 million in the same period last year, primarily due to higher selling, general, and administrative expenses.
• The operating loss was $2.5 million, compared to $2.2 million in the prior year.
• Interest expense increased significantly to $2.5 million, up from $0.8 million in the prior year, due to the issuance of new convertible senior notes.
• The net loss for the quarter was $5.5 million, or $0.09 per share, compared to a net loss of $2.1 million, or $0.03 per share, in the prior year.
• The company's backlog increased to approximately $219 million, compared to $189 million at the end of the same quarter in fiscal 2024.
• Cash and cash equivalents were $33.4 million as of July 31, 2024, down from $38.1 million at the end of the previous quarter.

Sentiment

Score: 4

Explanation: The document presents mixed results. While revenue increased and backlog grew, the company's net loss widened, and operating expenses rose significantly. The company also faces several risks, including reliance on a limited number of customers and the complexity of its manufacturing services. The sentiment is therefore cautiously negative.

Positives

• The company experienced a 6% increase in overall revenue, indicating growth in its business.
• The increase in process development revenue suggests a strong demand for the company's development services.
• The company's backlog increased to $219 million, indicating future revenue potential.
• The company successfully remediated a material weakness in internal control over financial reporting.

Negatives

• The company reported a net loss of $5.5 million for the quarter, an increase from the $2.1 million loss in the prior year.
• Operating expenses increased by 30%, primarily due to higher selling, general, and administrative costs.
• Interest expense increased significantly due to the issuance of new convertible senior notes.
• Cash and cash equivalents decreased by $4.7 million during the quarter.

Risks

• The company relies on a limited number of customers for a significant portion of its revenue.
• The company generally does not have long-term contracts with customers, which exposes it to market and competitive price pressures.
• The company is making a significant investment in viral vector development and manufacturing, which involves risks and uncertainties.
• The company's manufacturing facilities are all located in Orange County, California, which increases its exposure to disruptions.
• The company's manufacturing services are highly complex, and any failure to provide quality and timely services could harm its business.
• The company is subject to stringent and evolving laws, regulations, and rules related to data privacy and security.
• The company's information technology systems, or those of third parties, could be compromised, leading to adverse consequences.
• The company may not have sufficient cash flow to make payments on its debt when due.

Future Outlook

The company anticipates that a significant amount of its backlog will be recognized as revenue over the next five fiscal quarters. The company believes that its existing cash and cash equivalents on hand and its anticipated cash flows from operating activities will be sufficient to fund its operations for at least the next 12 months.

Management Comments

• The company's growth strategy seeks to align with the growth of the biopharmaceutical drug substance contract services market.
• The company aims to invest in additional capacity, capabilities, and resources to meet customer demand.
• The company intends to broaden its market awareness through a diversified marketing strategy.
• The company plans to expand its customer base and programs with existing customers.
• The company will explore and invest in strategic opportunities to enhance its capabilities.
• The company seeks to increase its operating profit margin to best-in-class within the industry.

Industry Context

The company operates in the competitive contract development and manufacturing organization (CDMO) market, which is experiencing growth due to the increasing demand for outsourced biologics manufacturing. The company's expansion into viral vector development and manufacturing aligns with the growing cell and gene therapy market.

Comparison to Industry Standards

• The company's 6% revenue growth is a positive sign, but it is important to compare this to the growth rates of other CDMOs in the same sector, such as Catalent, Lonza, and Samsung Biologics, to assess its relative performance.
• The gross margin of 14% is relatively low compared to some of the larger CDMOs, which often have gross margins in the 20-30% range, indicating potential areas for improvement in cost management.
• The increase in operating expenses is a concern, and the company needs to demonstrate that it can achieve economies of scale as it grows to improve its profitability.
• The company's backlog of $219 million is a positive indicator of future revenue, but it is important to monitor the conversion rate of backlog to actual revenue and compare it to industry benchmarks.
• The company's cash position of $33.4 million is relatively low compared to some of its larger competitors, which may limit its ability to invest in future growth opportunities.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and the decrease in cash and cash equivalents.
• Employees may be affected by the company's growth and expansion plans.
• Customers may benefit from the company's increased capacity and capabilities.
• Suppliers may see increased demand for their products as the company expands its operations.
• Creditors may be concerned about the company's ability to service its debt.

Next Steps

• The company will continue to invest in additional capacity, capabilities, and resources.
• The company will broaden its market awareness through a diversified marketing strategy.
• The company will expand its customer base and programs with existing customers.
• The company will explore and invest in strategic opportunities to enhance its capabilities.
• The company will focus on increasing its operating profit margin.

Key Dates

Keywords

CDMO, contract manufacturing, biologics, process development, manufacturing revenues, biopharmaceutical, convertible notes, backlog, financial results, revenue growth